Cellectis S.A.

Cellectis S.A. is a clinical-stage biotechnology company developing allogeneic CAR-T cell therapies for cancer treatment. The company’s product development pipeline, as detailed in its annual SEC Form 20-F filings, is built on a foundation of preclinical animal testing. These filings consistently disclose that advancement of its therapeutic candidates into human clinical trials is contingent on “results of product development, laboratory and animal studies” and that “testing in animal studies” is a standard part of its research process. The company explicitly notes that results from these animal studies may not be sufficiently compelling to warrant further development.

As a pharmaceutical developer, Cellectis operates within a regulatory framework that currently mandates animal testing to evaluate the safety and efficacy of novel cell therapies before they can be tested in humans. The company’s disclosures confirm that animal testing is not an ancillary activity but an integral, funded component of its core business model for bringing new drugs to market.